
NeoCast™
NeoCast is a solvent-free liquid embolic material. It’s shear-responsive property uniquely enables deep penetration of target vessels while minimizing the risk of non-target embolization. Within minutes the biomaterial cures into an elastomeric solid providing a complete durable occlusion.
NeoCast’s promising characteristics are expected to demonstrate utility across clinical applications where deep vessel penetration is desired.
Clinical Experience with MMA embolization: One Vessel, Two Indications

A chronic subdural hematoma is a type of persistent bleeding that accumulates on the brain’s surface (dura), often resulting from a fall or trauma to the head. The accumulated blood can put pressure on the brain. cSDH is considered the fastest growing neurosurgical condition and has been categorized as a sentinel health event in the elderly.
Middle meningeal artery embolization (MMAe) blocks blood flow within the artery and branching vessels that supply the hematoma. This procedure is emerging as an alternative or adjunct modality to conventional surgery to treat and prevent cSDH recurrence.

Patients undergoing surgical resection of hypervascular axial brain tumors, such as meningiomas, are at risk of significant blood loss, making surgery time-consuming and technically difficult.
Pre-operative embolization (POE) of the middle meningeal artery (MMA) blocks blood flow to the vessels supplying the tumor and facilitates surgical removal. This minimally invasive technique is reported to improve functional patient outcomes and recurrence-free survival compared to patients who did not undergo POE.1,2

REFERENCES
- Schartz, D., et al., Preoperative Embolization of Meningiomas Facilitates Reduced Surgical Complications and Improved Clinical Outcomes. Clinical Neuroradiology, 2023.
- Akimoto, T., et al., Preoperative tumor embolization prolongs time to recurrence of meningiomas: a retrospective propensity-matched analysis. Journal of NeuroInterventional Surgery, 2022: p. neurintsurg-2022-019080.
